Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
出版年份 2023 全文链接
标题
Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)
作者
关键词
-
出版物
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
Volume 208, Issue 4, Pages 406-416
出版商
American Thoracic Society
发表日期
2023-06-27
DOI
10.1164/rccm.202306-0944oc
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Relationship of COPD Exacerbation Severity and Frequency on Risks for Future Events and Economic Burden in the Medicare Fee-For-Service Population
- (2022) Sanjay Sethi et al. International Journal of Chronic Obstructive Pulmonary Disease
- Treatment Patterns for Chronic Obstructive Pulmonary Disease (COPD) in the United States: Results from an Observational Cross-Sectional Physician and Patient Survey
- (2022) David Mannino et al. International Journal of Chronic Obstructive Pulmonary Disease
- Towards the elimination of chronic obstructive pulmonary disease: a Lancet Commission
- (2022) Daiana Stolz et al. LANCET
- A Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy
- (2021) Gary T Ferguson et al. International Journal of Chronic Obstructive Pulmonary Disease
- Dysfunctional Bronchial Cilia Are a Feature of Chronic Obstructive Pulmonary Disease (COPD)
- (2021) Biju Thomas et al. COPD-Journal of Chronic Obstructive Pulmonary Disease
- Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline
- (2020) Linda Nici et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
- (2020) Klaus F. Rabe et al. NEW ENGLAND JOURNAL OF MEDICINE
- THE PHOSPHODIESTERASE INHIBITOR ENSIFENTRINE REDUCES PRODUCTION OF PRO-INFLAMMATORY MEDIATORS IN WELL-DIFFERENTIATED BRONCHIAL EPITHELIAL CELLS BY INHIBITING PDE4.
- (2020) Mark Turner et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Symptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD – A Detailed Analysis
- (2020) Henrik Watz et al. International Journal of Chronic Obstructive Pulmonary Disease
- Prospects for COPD treatment
- (2020) Maria Gabriella Matera et al. CURRENT OPINION IN PHARMACOLOGY
- Phosphodiesterases as therapeutic targets for respiratory diseases
- (2019) Haoxiao Zuo et al. PHARMACOLOGY & THERAPEUTICS
- The future of bronchodilation: looking for new classes of bronchodilators
- (2019) Mario Cazzola et al. European Respiratory Review
- Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
- (2018) David A. Lipson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Symptomatic burden of COPD for patients receiving dual or triple therapy
- (2018) Stephanie Chen et al. International Journal of Chronic Obstructive Pulmonary Disease
- The dual phosphodiesterase 3 and 4 inhibitor RPL554 stimulates CFTR and ciliary beating in primary cultures of bronchial epithelia
- (2016) Mark J. Turner et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
- Novel relaxant effects of RPL554 on guinea pig tracheal smooth muscle contractility
- (2016) R Venkatasamy et al. BRITISH JOURNAL OF PHARMACOLOGY
- Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways
- (2015) Luigino Calzetta et al. PULMONARY PHARMACOLOGY & THERAPEUTICS
- Cardiovascular Safety of Inhaled Long-Acting Bronchodilators in Individuals With Chronic Obstructive Pulmonary Disease
- (2013) Andrea Gershon et al. JAMA Internal Medicine
- Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials
- (2013) Lui G Franciosi et al. Lancet Respiratory Medicine
- Inhaled Anticholinergic Drug Therapy and the Risk of Acute Urinary Retention in Chronic Obstructive Pulmonary Disease
- (2011) Anne Stephenson et al. ARCHIVES OF INTERNAL MEDICINE
- Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages
- (2011) J. Milara et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
- (2010) John R. Hurst et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease
- (2009) Katharine H Banner et al. BRITISH JOURNAL OF PHARMACOLOGY
- Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
- (2009) Leonardo M Fabbri et al. LANCET
- Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
- (2009) Peter MA Calverley et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search